NLS PHARMACEUTICS LTD and VSTOCK Transfer LLC, as Warrant Agent Warrant Agency Agreement Dated as of _________, 2020 WARRANT AGENCY AGREEMENTWarrant Agency Agreement • November 13th, 2020 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of [ ] __, 2020 (“Agreement”), between NLS Pharmaceutics Ltd., a corporation organized under the laws of Switzerland (the “Company”), and VStock Transfer LLC, a corporation organized under the laws of [ ] (the “Warrant Agent”).
COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTDCommon Share Purchase Warrant • November 13th, 2020 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations • New York
THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [_____], 20__1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from NLS Pharmaceutics Ltd., a company incorporated under the laws of Switzerland, with its registered office at Stans, Switzerland and registered with the commercial register of the Canton of Nidwalden under company number CHE-447.067.367 (the “Company”), up to [___] of our Common Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of
NLS PHARMACEUTICS LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • November 13th, 2020 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations • New York
The undersigned, NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), an aggregate of ________ units (the “Firm Units” or “Units”) of the Company’s securities, and, at the election of the Representative, up to an additional ________ Option Shares (as defined herein and collectively with the Common Shares (as defined below) underlying the Firm Units, the “Shares”), and/or up to an additional _________ Option Warrants (as defined herein and collectively with warrants underlying the Firm Units, the “Warrants”). Each Unit consists of one Common Share (the “Firm Shares”) of the Company, par value CHF 0.02 per share (the “Common Shares”) and on
